John G. Cox

John G. Cox

President and Chief Executive OfficeratDyne Therapeutics· In proxies 2023–2025

Pay in FY2024Dyne Therapeutics stock +77.1% the same year

John G. Cox was paid $20.7M in FY2024 (Dec). Dyne Therapeutics stock rose 77.1% that year.

Pay$100 in the stock at the end of FY23 → $177
Pay is from the Summary Compensation Table of each Dyne Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Dyne TherapeuticsPublic company · 3 yr
    • President and Chief Executive Officer2023 – Present · 3 yrStock in role +51%
  2. Canopy-Immuno Therapeutics Ltd.Public company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Minovia Therapeutics Ltd.Public company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years
  4. Sigilon Therapeutics, Inc.Public company · 4 yr
    • Director2019 – 2023 · 4 yrNo stock prices for these years
  5. Repligen CorporationPublic company · 6 yr
    • Director2014 – 2020 · 6 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?